|
rs1800795
|
|
|
0.060 |
GeneticVariation |
BEFREE |
We genotyped rs1800795 in overweight/obese women (<i>N</i> = 242) who were randomly assigned to a lower fat (20% energy), higher carbohydrate (65% energy) diet; a lower carbohydrate (45% energy), higher fat (35% energy) diet; or a walnut-rich (18% energy), higher fat (35% energy), lower carbohydrate (45% energy) diet in a 1-year weight loss intervention study of obesity-related biomarkers for breast cancer incidence and mortality.
|
28555011 |
2017 |
|
rs1800795
|
|
|
0.060 |
GeneticVariation |
BEFREE |
These findings suggest that GG SNP at IL-6: rs1800795 may indicate an increased risk of metastasis of primary breast cancer.
|
28732081 |
2017 |
|
rs1800795
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Mutant allele and genotype at IL-1β [+3954 C>T (rs1143634)] site associated with increased BC risk, while mutant allele and genotypes at IL-6 [-174 G>C (rs1800795)] polymorphism appeared to be protective.
|
22818022 |
2012 |
|
rs1800795
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The association between a single-nucleotide polymorphism (SNP) -174G > C (rs1800795) located in the IL-6 gene promoter and breast cancer risk is still controversial and ambiguous.
|
20043205 |
2010 |
|
rs1800795
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Among women without recent hormone exposure, those with a WHR >0.9 and the rs1800795 GG genotype had a greater than threefold increased risk of bre</span>ast cancer (odds ratios (ORs) 3.22, 95% confidence intervals (CIs) 1.27, 817) when compared with women with a WHR <0.8 and the rs1800795 GG genotype (P interaction 0.01).
|
18239642 |
2008 |
|
rs1800795
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Among postmenopausal women not recently exposed to hormones, the AG/GG genotypes of rs1800797 (-596A>G) and the GC/CC genotypes of rs1800795 (-174G>C) significantly reduced risk of breast cancer among non-Hispanic white women [odds ratio (OR), 0.69; 95% confidence interval (95% CI), 0.48-1.00 and OR, 0.68; 95% CI, 0.47-0.99, respectively] and Hispanic/Native American women (OR, 0.48; 95% CI, 0.28-0.83 and OR, 0.44; 95% CI, 0.26-0.99, respectively).
|
17416766 |
2007 |
|
rs1800797
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Additionally, rs1800797 was significantly association with breast cancer, non-Hodgkin's lymphoma, B-cell lymphoma and diffuse large B-cell lymphoma but not gastric cancer.
|
29552316 |
2018 |
|
rs1800796
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results suggest that the contribution of diabetes to breast cancer risk might be modified by IL-6 rs1800796 and HSPD1 rs2605039.
|
28591216 |
2017 |
|
rs1800796
|
|
|
0.020 |
GeneticVariation |
BEFREE |
IL6 genotype and haplotype significantly modified the association between aspirin and breast cancer, with the greatest effect modification being among women not recently exposed to hormones [P interaction = 0.06 (for non-Hispanic white) and 0.04 (for Hispanic/Native American) and SNP rs1800796 or -572G>C].
|
17416766 |
2007 |
|
rs1800797
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Among postmenopausal women not recently exposed to hormones, the AG/GG genotypes of rs1800797 (-596A>G) and the GC/CC genotypes of rs1800795 (-174G>C) significantly reduced risk of breast cancer among non-Hispanic white women [odds ratio (OR), 0.69; 95% confidence interval (95% CI), 0.48-1.00 and OR, 0.68; 95% CI, 0.47-0.99, respectively] and Hispanic/Native American women (OR, 0.48; 95% CI, 0.28-0.83 and OR, 0.44; 95% CI, 0.26-0.99, respectively).
|
17416766 |
2007 |
|
rs2069861
|
|
|
0.010 |
GeneticVariation |
BEFREE |
There was a significantly increased risk of breast cancer associated with one or more C>T alleles at IL6 rs2069861 among subjects in the oldest age group (OR 1.8, 95% CI 1.1-2.9), but no overall increased risk of breast cancer associated with any IL6 or IL6R variants in the combined data.
|
21523452 |
2011 |
|
rs2069832
|
|
|
0.010 |
GeneticVariation |
BEFREE |
HAI pre-menopausal women who were exposed to 10+ h of passive smoke per week and had the rs2069832 IL6 GG genotype had over a fourfold increased risk of breast cancer (OR 4.4, 95% CI 1.5-12.8; P for interaction 0.01).
|
17594514 |
2008 |